Drug Profile
Research programme: diabetes therapeutics - Sanofi/University of California at San Francisco
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Sanofi; University of California at San Francisco
- Class Small interfering RNA
- Mechanism of Action RNA interference; Small interfering RNA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Diabetes-mellitus in USA
- 10 Jan 2012 Early research in Diabetes mellitus in USA (unspecified route)